Leading the project are Dr. Mone Zaidi from Icahn Mount Sinai and Dr. Clifford J. Rosen from the MaineHealth Institute for Research.
Previous research from Dr. Ziadi indicates that inhibiting FSH increases bone mass and reduces body fat and neurodegeneration. Continuing research regarding this aging-related hormone could pave the way for new treatments for associated conditions like obesity, osteoporosis, menopause and Alzheimer’s disease.
The funding is provided by the National Institutes of Health and will be awarded annually in increments of $4.2 million for the next five years.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
